The international PCT patent portfolio continues to expand, now covering seven countries and regions.

Kebeijia has consistently adhered to a strategy of independent intellectual property ownership. To date, we have secured 12 international PCT patents in the areas of natural plant active ingredient extraction, formulation processes, and applications, covering seven countries and regions: China, the United States, the European Union, Canada, Japan, Australia, and Singapore.

Leveraging its patent portfolio, the company has secured authorization from U.S.-based HUYA to submit a registration application for a new class of drugs (Registration No. HB1-3802). Preclinical studies are complete, paving the way for international expansion.